Regeneron, Sanofi win a delayed OK for rheumatoid arthritis IL-6 heavyweight sarilumab
It took more than six months and likely caused more than a few red faces, but Sanofi has dealt with the FDA’s issues with its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
